Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 34Cisplatin 21Capecitabine 18Oxaliplatin 15Leucovorin 10Fluorouracil 10Irinotecan 8Erlotinib Hydrochloride 7pembrolizumab 5Bevacizumab 5Radiotherapy 4Carboplatin 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Watchful Waiting 3Taxes 3Sorafenib 3Platinum 3Interleukin-12 Subunit p35 3Immunohistochemistry 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3trifluridine tipiracil drug combination 2tremelimumab 2regorafenib 2durvalumab 2dehydroftorafur 2Trastuzumab 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gallbladder Neoplasms × merestinib × Clear all
NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
19 enrolled
GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡